000			03713nam a22004215i 4500
001			86574
003			ES-MaUEC
005			20230207040605.0
007			cr nn 008mamaa
008			160201s2016 ja | s |||| 0|eng d
020			_a9784431556787
040			_aES-MaUEC
050		4	_aRC935.M7 _b2016 EB
082	0	4	_a616.8
245	0	0	_aTranslational research in muscular dystrophy _cedited by Shin'ichi Takeda, Yuko Miyagoe-Suzuki, Madoka Mori-Yoshimura
250			_a1st ed.
260			_aTokyo _bSpringer _c2016
300			_a1 recurso en línea (VIII, 199 p.) _b35 ilustraciones, 13 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Fukuyama congenital muscular dystrophy - Clinical aspects -- 2. -Dystroglycanopathy -- 3. Myotonic dystrophy -- 4. Molecular pathogenesis and therapeutic strategy in GNE myopathy -- 5. Targeting the type I TGF- receptor for treating caveolin-3-deficient autosomal dominant limb-girdle muscular dystrophy type 1C and muscle wasting disorders -- 6. Translational Research in Nucleic Acid Therapies for Muscular Dystrophies -- 7. Toward regenerative medicine for muscular dystrophies-Lessons from regeneration processes- -- 8. Stem cell-based therapy for Duchenne muscular dystrophy -- 9. Therapeutic approach of iPS cell technology for treating muscular dystrophy -- 10. Clinical aspects of GNE myopathy and translational medicine -- 11. Patient registries for international harmonized clinical development -- 12. Muscular Dystrophy Clinical Trial Network in Japan -- 13. Translational research on DMD in Japan From mice to exploratory investigator-initiated clinical trial in humans
520			_aThis book presents recent advances in translational research on muscular dystrophy (MD) to physicians and researchers, including cutting-edge research on the disease such as regenerative medicine, next-generation DNA sequencing, and nucleic acid therapies. It also describes the current systems for clinical trials and MD patient databases, resources, which will support the early realization of clinical application and improve patients' quality of life. MD is the one of the most widely known inherited neuromuscular diseases and is classified into diverse types by symptoms, age of onset, mode of inheritance, and clinical progression. With the development of molecular biology, the occurrence mechanisms of each type of MD are gradually being elucidated. Although there is no known permanent cure yet, the stage of treatment research has now advanced to clinical trials Notas Forma de acceso: World Wide Web
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aDistrofia muscular _9145524 _0comprobar BNE19920886754 _2embne
650		7	_aTerapia genética _0comprobar BNE19960202071 _2embne _9150702
650		7	_aBiología molecular _0comprobar BNE19900968373 _2embne _9139103
700	1		_aTakeda, Shin'ichi _eeditor literario _9100394 _0Local
700	1		_aMiyagoe-Suzuki, Yuko _eeditor literario _9100395 _0Local
700	1		_aMori-Yoshimura, Madoka _eeditor literario _9100396 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-55678-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9784431556787
907			_a.b12958529 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b08-06-17 _cm _dz _eb _feng _gja _h0
945			_aRC935 .M7 T73 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1160010x _z06-04-17
999			_c86574 _d86574 _x1